ArcticZymes flytter inn i Oslo
ArcticZymes Technologies to establish an Application Development Laboratory at ShareLab in Oslo
Tromsø, Norway, 9[th] March 2022 - ArcticZymes Technologies ASA (OSE: AZT)
announces the establishment of a new application development laboratory at
ShareLab in Oslo.
ArcticZymes Technologies has signed an agreement with ShareLab AS to lease
laboratory facilities at its premises in the Oslo Science Park. These facilities
will support application development activities to demonstrate the utility of
the Company´s enzymes in customer relevant workflows and technologies. This is
an essential part of the innovation process and strengthens the commercial value
proposition of the Company´s product offerings.
ShareLab is a service platform provider of laboratory and office facilities to
biotechnology companies. It conveniently provides the necessary amenities and
shared core equipment suited to ArcticZymes´ requirements which means minimal
capital investments to get started. Furthermore, ShareLab´s location in the Oslo
Science Park is central to the Norwegian biotechnology industry and life science
research.
The Oslo location will allow access to a broad talent pool of commercially
-experienced application scientists. Also, as the Company continues to grow it
has strategic relevance to have part of ArcticZymes located at the heart of the
Norwegian biotech industry.
Dr. Darren Ellis has been hired to lead the activities at ShareLab and is
currently recruiting two application scientists. Dr. Ellis brings over 20 years
of industrial R&D experience (from Solexa (now Illumina) and Thermo Fisher
Scientific) in leading and developing molecular research and In Vitro Diagnostic
(IVD) applications, technologies, and products. Furthermore, he has global
expertise in Business-to-Business (B2B) application development, successfully
helping commercial partners/customers to bring their technologies and product
developments to market.
ArcticZymes Technologies ASA, CEO, Jethro Holter said:
"ArcticZymes is delighted to welcome Dr. Ellis to lead this important expansion
into Oslo. The new applications team and laboratory are integral to the
Company´s growth strategy to broaden the utility and relevance of ArcticZymes´
enzymes to its commercial customers.
ArcticZymes is proud to partner with ShareLab and become an active member of the
Oslo Biotech community."
ShareLab AS, Managing Partner, Esben A. Nilssen, said:
"ArcticZymes is Norway's premier industrial biotech company, and we are both
happy and proud to welcome them as new members of ShareLab. At ShareLab,
ArcticZymes will benefit from the interaction with biotech talents, life science
institutions, and companies located at and around ShareLab and Oslo Science
Park. Deep enzymes expertise is much sought after and ArcticZymes' presence at
ShareLab will undoubtedly cater for growth."
Tromsø, Norway, 9[th] March 2022 - ArcticZymes Technologies ASA (OSE: AZT)
announces the establishment of a new application development laboratory at
ShareLab in Oslo.
ArcticZymes Technologies has signed an agreement with ShareLab AS to lease
laboratory facilities at its premises in the Oslo Science Park. These facilities
will support application development activities to demonstrate the utility of
the Company´s enzymes in customer relevant workflows and technologies. This is
an essential part of the innovation process and strengthens the commercial value
proposition of the Company´s product offerings.
ShareLab is a service platform provider of laboratory and office facilities to
biotechnology companies. It conveniently provides the necessary amenities and
shared core equipment suited to ArcticZymes´ requirements which means minimal
capital investments to get started. Furthermore, ShareLab´s location in the Oslo
Science Park is central to the Norwegian biotechnology industry and life science
research.
The Oslo location will allow access to a broad talent pool of commercially
-experienced application scientists. Also, as the Company continues to grow it
has strategic relevance to have part of ArcticZymes located at the heart of the
Norwegian biotech industry.
Dr. Darren Ellis has been hired to lead the activities at ShareLab and is
currently recruiting two application scientists. Dr. Ellis brings over 20 years
of industrial R&D experience (from Solexa (now Illumina) and Thermo Fisher
Scientific) in leading and developing molecular research and In Vitro Diagnostic
(IVD) applications, technologies, and products. Furthermore, he has global
expertise in Business-to-Business (B2B) application development, successfully
helping commercial partners/customers to bring their technologies and product
developments to market.
ArcticZymes Technologies ASA, CEO, Jethro Holter said:
"ArcticZymes is delighted to welcome Dr. Ellis to lead this important expansion
into Oslo. The new applications team and laboratory are integral to the
Company´s growth strategy to broaden the utility and relevance of ArcticZymes´
enzymes to its commercial customers.
ArcticZymes is proud to partner with ShareLab and become an active member of the
Oslo Biotech community."
ShareLab AS, Managing Partner, Esben A. Nilssen, said:
"ArcticZymes is Norway's premier industrial biotech company, and we are both
happy and proud to welcome them as new members of ShareLab. At ShareLab,
ArcticZymes will benefit from the interaction with biotech talents, life science
institutions, and companies located at and around ShareLab and Oslo Science
Park. Deep enzymes expertise is much sought after and ArcticZymes' presence at
ShareLab will undoubtedly cater for growth."
rufus01
09.03.2022 kl 09:00
1720
Dette var vel forventet, men at det var Dr Darren Ellis som virker og være en type med ett bredt erfaringsgrunnlag fra både Illumina og Thermo Fisher som skal lede dette må være svært positivt. Kanskje lov og håpe på en liten opptur idag. Det hadde både aksjonærer og AZT fortjent :)
Nå søker AZT etter ny stilling USA.
ArcticZymes is looking to hire a junior Business Development Manager in the United States. Are you ready to take the next step in your career with a world leader in the development and commercialization of unique enzymes for molecular biology and gene and cell therapy? A minimum of 1 – 3 years of commercial experience is all you need to elevate your career. If yes, send a CV to dino.dicamillo@arcticzymes.com #ArcticZymesTechnologies #nowhiring #joboffer #jobsearch #recruitment #businessdevelopmentjobs
ArcticZymes is looking to hire a junior Business Development Manager in the United States. Are you ready to take the next step in your career with a world leader in the development and commercialization of unique enzymes for molecular biology and gene and cell therapy? A minimum of 1 – 3 years of commercial experience is all you need to elevate your career. If yes, send a CV to dino.dicamillo@arcticzymes.com #ArcticZymesTechnologies #nowhiring #joboffer #jobsearch #recruitment #businessdevelopmentjobs
rufus01
11.03.2022 kl 19:23
1260
Aksjekursen går ned, mens arbeidsstokken til AZT vokser. Dette er bra og viser at det ikke er noen hvileskjær i dette firmaet. Så får vi satse på at trenden snart snur, og at kursen følger etter i takt med dette voksende selskapet. Er overbevist om kurstoppen enda ikke er nådd. Her er det bare og holde hodet kaldt, så er jeg sikker på at alle vil bli rikt belønnet iløpet av ett år eller to!
bj111
11.03.2022 kl 23:10
1145
Viktigste er at selskapet vokser og genererer inntekter større enn utgiftene. Så lenge de fortsetter med det vil kursen komme oppover på sikt. Og kurstoppen er selvsagt da ikke nådd på siste ATH. Vi skal nok forbi den men det tar nok noe tid med det makrobildet en ser i dag.